Vir Biotechnology doses first patient in Phase I VIR-5500 trial

​Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of VIR-5500 for metastatic prostate cancer.

The post Vir Biotechnology doses first patient in Phase I VIR-5500 trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Viome PRO introduces blood test for pancreatic cancer
Alpheus begins multi-centre study for butterfly GBM
Biohaven partners with Ono in $100m IgG degrader deal
The pitfalls in hospitals’ ability to auction clinical labour
BD reports nine-month AGILITY trial data for Revello stent

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us